[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555908":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":35,"centralContacts":39,"locations":49,"responsibleParty":62,"collaborators":65,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":73,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":26,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":100,"whyStopped":26,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Universidad de Granada","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention Group","EXPERIMENTAL","Health recommendations (educational videos) + Individualised exercise intervention",[13,14],"Behavioral: Individualised health recommentations","Behavioral: Individualised physical exercise program",{"label":16,"type":6,"description":17,"interventionNames":18},"Control Group","Health recommendations (educational videos)",[19],"Behavioral: General health recommendations",[21,27,31],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"BEHAVIORAL","Individualised health recommentations","Individualised recommendations for physical activity and exercise, lifestyle, stress management and symptom management with solid scientific evidence established by health organisations and scientific reference committeess through the ATOPE-PRO mobile application based on patients reported status.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"General health recommendations","Recommendations for physical activity and exercise, lifestyle, stress management and symptom management with solid scientific evidence established by health organisations and scientific reference committeess through the ATOPE-PRO mobile application.",[16],{"type":22,"name":32,"description":33,"armGroupLabels":34,"otherNames":26},"Individualised physical exercise program","Follow-up of an individualised exercise program adjusted by daily monitoring of the level of physical, physiological and psychological condition.",[9],[36],{"name":37,"affiliation":5,"role":38},"Irene Cantarero Villanueva, PhD","PRINCIPAL_INVESTIGATOR",[40,45],{"name":37,"role":41,"phone":42,"phoneExt":43,"email":44},"CONTACT","637007250","+34","irenecantarero@ugr.es",{"name":46,"role":41,"phone":47,"phoneExt":43,"email":48},"Isabel Blancas López-Barajas, PhD","958257235","iblancas@ugr.es",[50],{"facility":51,"status":26,"city":52,"state":26,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":26},"University of Granada","Granada","18016","Spain","ES",{"type":57,"coordinates":58},"Point",[59,60],-3.60667,37.18817,{"lat":60,"lon":59},{"type":38,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Irene Cantarero Villanueva","Principal Investigator",[66,69],{"name":67,"class":68},"Instituto de Salud Carlos III","OTHER_GOV",{"name":70,"class":6},"Hospital Clinico Universitario San Cecilio","100555908","preventing-breast-cancer-therapy-related-cardiovascular-toxicity-with-a-daily-adapted-program-with-mhealth-support-100555908",false,"NCT06518200","Preventing Breast Cancer Therapy-related Cardiovascular Toxicity With a Daily-adapted Program With Mhealth Support","ATOPE-PRO: Effects on the Prevention of Breast Cancer Therapy-related Cardiovascular Toxicity of a Daily-adapted and Individualized Program With Support From a Mobile Application","ATOPE-PRO","Inclusion Criteria:\n\n* Recently diagnosed with stage I-III breast cancer\n* Treatments predisposing to cardiotoxicity (anthracyclines, targeted therapies, radiotherapy)\n* Signed informed consent form\n* Medical authorisation to participate\n* Smartphone user level\n\nExclusion Criteria:\n\n* Patient underwent previous cancer treatments.\n* Patients were previously diagnosed with cancer\n* Pregnant patients. Patients performing other type of therapeutic exercise at diagnosis time with an intake \\>or = to 150 moderate-intensity or 75 min of vigorous-intensity a day\n* Therapeutic exercise practice not recommended because psychiatric or cognitive disorders or cute or chronic condition that prevents exercise (advanced lung disease, oxygen requirement, stenosis \\>70%, metastasis etc.).","FEMALE","18 Years","65 Years",{"count":83,"type":84},102,"ESTIMATED","INTERVENTIONAL",[87],"NA","ATOPE-PRO, was developed with the intention of consolidating the integration of an innovative system for the prevention of cancer therapy-related cardiovascular toxicity (CTR-CVT) in the continuum care of women with breast cancer in health services. It is a step further towards personalized medicine by optimizing the already available tools and integrating artificial intelligence. Breast cancer survival increases every year, a situation that poses new challenges for health professionals. The European Society for Medical Oncology, a reference in Europe, has just highlighted the need to anticipate to and prevent sequelae derived from the disease and its treatments. This, in addition to having a positive impact on improving the quality of life of people suffering from this disease, would mean a reduction in the risk of recurrence, the appearance of other tumors and other diseases, and death from cancer or other causes, which have a personal impact and represent an overload of the healthcare system. To this end, ATOPE- PRO aims to optimize and refine tools already developed in the previous project (ATOPE, Pl18\u002F01840), integrating artificial intelligence to help identify CTR-CVT, risk profiles, and effective and safe doses (at a clinical level) early on, implementing the program in a longer term, and transferring the results to the social sector (social level). The project has 4 stages: Phase 0 or start-up (to make improvements and analyse usability); Phase 1 for piloting and optimization; Phase 2, to verify efficacy (randomized controlled clinical trial) and Phase 3, in which a deep analysis will be performed and future projects will be conceived.",[90],"Breast Cancer Female",[92,93,94,95,96,97,98,99],"Breast Neoplasms","Cancer therapy-related cardiovascular toxicity","Physical Exercise","Prevention","Quality of life","Rehabilitation","Telemedicine","Health related lifestyle","NOT_YET_RECRUITING","2026-04-30",{"date":103,"type":104},"2026-05-06","ACTUAL",{"date":106,"type":84},"2026-09-01",{"date":108,"type":84},"2028-12-31",{"name":5,"class":6},1]